Drug General Information
Drug ID	D03FCF
Former ID	DNCL001893
Drug Name	Novolimus
Indication	Restenosis [ICD10:I51.89]		Approved	[524566], [549817]
Company	Elixir Medical
Structure		Download 2D MOL
Target and Pathway
Target(s)	Serine/threonine-protein kinase mTOR	Target Info	Inhibitor	[543556]
KEGG Pathway	ErbB signaling pathway
	HIF-1 signaling pathway
	mTOR signaling pathway
	PI3K-Akt signaling pathway
	AMPK signaling pathway
	Insulin signaling pathway
	Thyroid hormone signaling pathway
	Adipocytokine signaling pathway
	Type II diabetes mellitus
	Pathways in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Glioma
	Prostate cancer
	Acute myeloid leukemia
	Central carbon metabolism in cancer
	Choline metabolism in cancer
PANTHER Pathway	Hypoxia response via HIF activation
	Interleukin signaling pathway
Pathway Interaction Database	IL4-mediated signaling events
	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
	IL12-mediated signaling events
	CDC42 signaling events
	LKB1 signaling events
	Regulation of Telomerase
	mTOR signaling pathway
	CXCR4-mediated signaling events
	EGFR-dependent Endothelin signaling events
	IL2 signaling events mediated by PI3K
	IFN-gamma pathway
	ErbB1 downstream signaling
	ErbB2/ErbB3 signaling events
	CXCR3-mediated signaling events
	Class I PI3K signaling events mediated by Akt
PathWhiz Pathway	Leucine Stimulation on Insulin Signaling
Reactome	PIP3 activates AKT signaling
	Macroautophagy
	mTORC1-mediated signalling
	HSF1-dependent transactivation
	CD28 dependent PI3K/Akt signaling
	VEGFR2 mediated vascular permeability
	TP53 Regulates Metabolic Genes
	Constitutive Signaling by AKT1 E17K in Cancer
WikiPathways	ErbB Signaling Pathway
	Senescence and Autophagy in Cancer
	Interferon type I signaling pathways
	Insulin Signaling
	EGF/EGFR Signaling Pathway
	Wnt Signaling Pathway Netpath
	Extracellular vesicle-mediated signaling in recipient cells
	Cardiac Hypertrophic Response
	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
	PIP3 activates AKT signaling
	Polycystic Kidney Disease Pathway
	Alpha 6 Beta 4 signaling pathway
	BDNF signaling pathway
	Oncostatin M Signaling Pathway
	Prostate Cancer
	TSLP Signaling Pathway
	FSH signaling pathway
	Leptin signaling pathway
	TSH signaling pathway
	RANKL/RANK Signaling Pathway
	SREBF and miR33 in cholesterol and lipid homeostasis
	Integrated Breast Cancer Pathway
	SREBP signalling
	Signaling by Insulin receptor
	Costimulation by the CD28 family
	Type II diabetes mellitus
	MicroRNAs in cardiomyocyte hypertrophy
	TOR Signaling
	AMPK Signaling
References
Ref 524566	ClinicalTrials.gov (NCT02009956) EXCELLA Post-Approval Study. U.S. National Institutes of Health.
Ref 549817	Clinical pipeline report, company report or official report of Elixir.
Ref 543556	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.